Cowen Reiterates Outperform on Codex DNA (DNAY), Remains Positive on Long-Term Outlook, Highlights Robust Growth of BioXp 9600 Despite Delayed Launch
Tweet Send to a Friend
Cowen analyst Steven Mah reiterated an Outperform rating and {REMOVEPT} price target on Codex DNA Inc. (NASDAQ: DNAY)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
